Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03260894
Title Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Incyte Corporation

renal cell carcinoma


Epacadostat + Pembrolizumab

Pazopanib + Sunitinib

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

No variant requirements are available.